Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy

Dongshao Chen, Zitong Zhao, Ruoxi Hong, Di Yang, Ying Gong, Qingnan Wu, Yan Wang, Yiren Cao, Jie Chen, Yidi Tai, Haoyu Liu, Jinting Li, Jiawen Fan, Weimin Zhang (), Yongmei Song () and Qimin Zhan ()
Additional contact information
Dongshao Chen: Chinese Academy of Medical Sciences
Zitong Zhao: Chinese Academy of Medical Sciences and Peking Union Medical College
Ruoxi Hong: Sun Yat-sen University Cancer Center
Di Yang: Chinese Academy of Medical Sciences
Ying Gong: Chinese Academy of Medical Sciences
Qingnan Wu: Chinese Academy of Medical Sciences
Yan Wang: Chinese Academy of Medical Sciences
Yiren Cao: Chinese Academy of Medical Sciences
Jie Chen: Chinese Academy of Medical Sciences
Yidi Tai: Chinese Academy of Medical Sciences
Haoyu Liu: Chinese Academy of Medical Sciences
Jinting Li: Chinese Academy of Medical Sciences
Jiawen Fan: Chinese Academy of Medical Sciences
Weimin Zhang: Chinese Academy of Medical Sciences
Yongmei Song: Chinese Academy of Medical Sciences and Peking Union Medical College
Qimin Zhan: Chinese Academy of Medical Sciences

Nature Communications, 2025, vol. 16, issue 1, 1-18

Abstract: Abstract The multifaceted roles and mechanisms of necroptosis in cancer cells remain incompletely understood. Here, we demonstrate that FGFR2 inhibition potently inhibits esophageal squamous cell carcinoma (ESCC) by inducing necroptosis in a RIP1/MLKL-dependent manner and show RIP3 is dispensable in this pathway. Notably, MST1 is identified as a necroptotic pathway component that interacts with RIP1 and MLKL to promote necroptosis by phosphorylating MLKL at Thr216. Additionally, FGFR2 inhibition induces Ser518 phosphorylation and triggers ubiquitin-mediated degradation of NF2, culminating in Hippo pathway suppression. Subsequently, YAP activation promotes RIP1 and MLKL transcriptional upregulation, further amplifying necroptosis. Intriguingly, IL-8 derived from necrotic cells stimulates peripheral surviving tumor cells to increase PD-L1 expression. Dual blockade of FGFR2/PD-L1 or FGFR2/IL-8-CXCR1/2 robustly impedes tumor growth in humanized mouse xenografts. Collectively, our findings delineate an alternative FGFR2-NF2-YAP signaling-dependent necroptotic pathway and shed light on the immunoregulatory role of FGFR2, offering promising avenues for combinatorial therapeutic strategies in clinical cancer management.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-59318-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59318-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-59318-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().